Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity

Tumor vasculature abnormality creates a microenvironment that is not suitable for anti-tumor immune response and thereby induces resistance to immunotherapy. Remodeling of dysfunctional tumor blood vessels by anti-angiogenic approaches, known as vascular normalization, reshapes the tumor microenviro...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-02, Vol.24 (5), p.4422
Main Authors: Tzeng, Hong-Tai, Huang, Yu-Jie
Format: Article
Language:English
Subjects:
Acidosis
Angiogenesis
Angiogenesis Inhibitors - therapeutic use
Antiangiogenics
Blood vessels
Breast cancer
Cytotoxicity
Endothelial cells
Endothelial Cells - pathology
Heterogeneity
Humans
Hypoxia
Immune checkpoint
Immune response
Immune system
Immunotherapy
Kinases
Ligands
Lymphocytes
Melanoma
Metabolism
Metabolites
Metastasis
Molecular modelling
Neoplasms - pathology
Neovascularization, Pathologic - pathology
Neutrophils
Permeability
Pharmacology
Physiology
Review
Signal transduction
T cell receptors
Tumor Microenvironment
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor vasculature abnormality creates a microenvironment that is not suitable for anti-tumor immune response and thereby induces resistance to immunotherapy. Remodeling of dysfunctional tumor blood vessels by anti-angiogenic approaches, known as vascular normalization, reshapes the tumor microenvironment toward an immune-favorable one and improves the effectiveness of immunotherapy. The tumor vasculature serves as a potential pharmacological target with the capacity of promoting an anti-tumor immune response. In this review, the molecular mechanisms involved in tumor vascular microenvironment-modulated immune reactions are summarized. In addition, the evidence of pre-clinical and clinical studies for the combined targeting of pro-angiogenic signaling and immune checkpoint molecules with therapeutic potential are highlighted. The heterogeneity of endothelial cells in tumors that regulate tissue-specific immune responses is also discussed. The crosstalk between tumor endothelial cells and immune cells in individual tissues is postulated to have a unique molecular signature and may be considered as a potential target for the development of new immunotherapeutic approaches.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24054422